Volume 90 Issue 16 | p. 43
Issue Date: April 16, 2012

GS-9620 by Gilead Sciences and BMS-791325 by Bristol-Myers Squibb

Medicinal chemists debut five drug candidates and describe their discovery.
Department: Science & Technology
Keywords: Medicinal chemistry, organic chemistry, ACS meetings, pharma, biotech, hepatitis, cancer, diabetes, migraine

Randall L. Halcomb, director of medicinal chemistry at Gilead Sciences in Foster City, Calif., revealed the structure of GS-9620, a potential drug for chronic hepatitis B as well as hepatitis C. The molecule is an orally administered agonist of Toll-like receptor 7 (TLR7), a receptor on immune cells that responds to virusderived RNA. Gilead’s scientists had a specific reason for targeting the immune system, Halcomb told C&EN. “In general when a hepatitis B patient goes . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society